Temsirolimus Is Highly Effective as Third-Line Treatment in Chromophobe Renal Cell Cancer

Publisher： Karger

E-ISSN： 1662-6575|4|1|16-18

ISSN： 1662-6575

Source： Case Reports in Oncology, Vol.4, Iss.1, 2011-01, pp. : 16-18

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Applicability of a Predictive Index for Second- and Third-Line Treatment of Unselected Non-Small-Cell Lung Cancer Patients

By  

Respiration, Vol. 82, Iss. 4, 2011-01 ,pp. : 341-350

Karger

Access to resources Recommend Favorite

Chromophobe Cell Renal Carcinoma

By  

Urologia Internationalis, Vol. 61, Iss. 3, 1999-02 ,pp. : 172-174

Karger

Access to resources Recommend Favorite

Efficacy of Temsirolimus after Previous Treatment with Sunitinib, Sorafenib or Everolimus in Advanced Renal Cell Cancer

By  

Oncology, Vol. 80, Iss. 1-2, 2011-05 ,pp. : 34-41

Karger

Access to resources Recommend Favorite

Initial Experience with Temsirolimus in 2nd-, 3rd- and 4th-Line Therapy for Metastatic Renal Cell Cancer: Good Clinical Response

By  

Urologia Internationalis, Vol. 86, Iss. 3, 2011-01 ,pp. : 256-260

Karger

Access to resources Recommend Favorite

Erlotinib for Metastatic Non-Small-Cell Lung Cancer: First-, Second- or Third-Line Setting – Does It Matter ?

By  

Oncology, Vol. 76, Iss. 2, 2008-12 ,pp. : 85-90

Karger

Access to resources Recommend Favorite